According to the report by Expert Market Research (EMR), the global hypoglossal nerve stimulation therapy market size is projected to grow at a CAGR of 13.2% between 2024 and 2032. Aided by the growing demand for innovative sleep apnea treatments and the rising prevalence of this disorder, the market is expected to grow significantly by 2032.
Hypoglossal nerve stimulation therapy is a relatively new treatment approach for obstructive sleep apnea, a disorder characterised by repeated interruptions in breathing during sleep due to a blockage of the upper airway. The therapy works by delivering mild stimulation to the hypoglossal nerve, which controls the movement of the tongue. By preventing the tongue from blocking the airway during sleep, the treatment allows patients to breathe normally and achieve a better quality of sleep.
The increasing global prevalence of obstructive sleep apnea is a significant driver behind the hypoglossal nerve stimulation therapy market growth. As the awareness around sleep apnea and its associated health risks increases, there has been a significant shift towards innovative treatments that can provide long-term relief with minimal side effects, such as hypoglossal nerve stimulation therapy. The market will continue to rise globally as favourable reimbursement circumstances for implantation procedures in these facilities are implemented.
In addition to its therapeutic benefits, hypoglossal nerve stimulation therapy is also a minimally invasive procedure, which reduces the risk of post-operative complications and makes it an appealing alternative to traditional treatment options. This quality is further aiding its acceptance among both patients and medical professionals, contributing to the therapy’s growing popularity.
Another critical factor accelerating the hypoglossal nerve stimulation therapy market development is the positive clinical outcomes associated with hypoglossal nerve stimulation therapy. Numerous studies have demonstrated the treatment’s effectiveness in improving breathing during sleep, reducing daytime sleepiness, and enhancing the overall quality of life for patients with obstructive sleep apnea.
Further, the rising investment in research and development activities is boosting the global hypoglossal nerve stimulation therapy market expansion. The expanding body of research is paving the way for advancements in technology and improved stimulation devices, which is likely to drive the market’s expansion over the forecast period.
Get a Free Sample Report with Table of Contents@ https://www.expertmarketresearch.com/reports/hypoglossal-nerve-stimulation-therapy-market/requestsample
Hypoglossal Nerve Stimulation Therapy Market Segmentation
The market can be divided based on treatment devices, product type, distribution channel, and region.
Market Breakup by Treatment Devices
• Aura 6000 Sleep Therapy System
• Inspire II Upper Airway Stimulation Device
Market Breakup by Product Type
• Battery Free
Market Breakup by Distribution Channel
• Hypermarkets and Supermarkets
• Pharmacies and Drug Stores
Market Breakup by Region
• North America
• Asia Pacific
• Latin America
• Middle East and Africa
The EMR report looks into the market shares, plant turnarounds, capacities, investments, and acquisitions and mergers, among other major developments, of the global hypoglossal nerve stimulation therapy companies. Some of the major key players explored in the report by Expert Market Research are as follows:
• Nyxoah SA.
• Fisher & Paykel Healthcare Limited
• Invacare Corporation
• Braebon Medical Corporation
Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skilful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.
EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.
Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.
Company Name: Claight Corporation
Contact Person: James Rowan, Business Consultant
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA